| Literature DB >> 24755473 |
Alexandra R Grassian1, Seth J Parker1, Shawn M Davidson1, Ajit S Divakaruni1, Courtney R Green1, Xiamei Zhang1, Kelly L Slocum1, Minying Pu1, Fallon Lin1, Chad Vickers1, Carol Joud-Caldwell1, Franklin Chung1, Hong Yin1, Erika D Handly1, Christopher Straub1, Joseph D Growney1, Matthew G Vander Heiden2, Anne N Murphy1, Raymond Pagliarini3, Christian M Metallo4.
Abstract
Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in several types of cancer, but the metabolic consequences of these genetic changes are not fully understood. In this study, we performed (13)C metabolic flux analysis on a panel of isogenic cell lines containing heterozygous IDH1/2 mutations. We observed that under hypoxic conditions, IDH1-mutant cells exhibited increased oxidative tricarboxylic acid metabolism along with decreased reductive glutamine metabolism, but not IDH2-mutant cells. However, selective inhibition of mutant IDH1 enzyme function could not reverse the defect in reductive carboxylation activity. Furthermore, this metabolic reprogramming increased the sensitivity of IDH1-mutant cells to hypoxia or electron transport chain inhibition in vitro. Lastly, IDH1-mutant cells also grew poorly as subcutaneous xenografts within a hypoxic in vivo microenvironment. Together, our results suggest therapeutic opportunities to exploit the metabolic vulnerabilities specific to IDH1 mutation. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24755473 PMCID: PMC4885639 DOI: 10.1158/0008-5472.CAN-14-0772-T
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312